Panbela Therapeutics (PBLA) Expected to Post Earnings on Wednesday

Panbela Therapeutics (OTCMKTS:PBLA) is anticipated to post its resultson Wednesday, August 12th. Analysts expect Panbela Therapeutics to post earnings of ($2,640.00) per share for the quarter.

Panbela Therapeutics Stock Performance

OTCMKTS:PBLA opened at $0.01 on Wednesday. The firm has a market capitalization of $53,835.00, a PE ratio of -0.00 and a beta of 42.81. The stock has a 50 day moving average of $0.01 and a 200-day moving average of $0.01. Panbela Therapeutics has a 52 week low of $0.00 and a 52 week high of $0.17.

Panbela Therapeutics Company Profile

Panbela Therapeutics, Inc (NASDAQ: PBLA) is a clinical‐stage biotechnology company focused on developing first‐in‐class therapies that modulate polyamine metabolism to treat aggressive cancers. The company’s lead investigational compound, SBP-101, is a proprietary stabilized spermine analogue designed to induce tumor cell apoptosis by dysregulating polyamine levels. Panbela has centered its pipeline largely on SBP-101 in combination with standard‐of‐care regimens for high‐mortality indications such as metastatic pancreatic adenocarcinoma and high‐risk myelodysplastic syndromes (HR-MDS).

In its pancreatic cancer program, Panbela is evaluating SBP-101 alongside gemcitabine and nab-paclitaxel in a Phase 1b/2 study, with interim data having been presented at major oncology conferences.